May 8, 2014 by Dan CarrollAT&T's Acquisition Interest Shakes Up the Dow's GainsCould AT&T buy DIRECTV? It's not a done deal by any means, but reports indicate the telecom giant's on the hunt for a big buy.
May 7, 2014 by Dan CarrollIs Abbott Laboratories Headed for a Breakup?Selling off non-core business has been all the rage in health care this year. Is Abbott Labs the next company to weigh a big sale in its quest for higher growth?
May 7, 2014 by Dan CarrollDisney's Earnings Boom Highlights the Dow's Hundred-Point JumpWhole Foods plunges on an otherwise strong day for investors.
May 7, 2014 by Dan CarrollCan This Struggling Industry Bounce Back?The cardiac rhythm management industry's been shaken up by sluggish sales and tough competition, but is a turnaround in the cards?
May 6, 2014 by Dan CarrollIs AstraZeneca's Dividend Unbeatable?AstraZeneca's in the news as Pfizer's big acquisitions target, but this stock offers one of the highest dividend yields around the industry. Is it worth your look?
May 6, 2014 by Dan CarrollWill These 3 Biotechs Bounce Back?These three biotech stocks have had a rough go over the past month, but can they make investors rich through the rest of 2014?
May 6, 2014 by Dan CarrollMerck, Pfizer Plunge to Lead the Dow's Triple-Digit DropBig Pharma dives on a big news day, with Merck completing a sale and Pfizer hot on the heels of an acquisition.
May 5, 2014 by Dan CarrollChina, Big Banking Hold Back the DowJPMorgan Chase and Goldman Sachs tumble as new worries over fixed income and equities revenue plagues the financial sector.
May 4, 2014 by Dan CarrollChina Could Pass the U.S. as the World's Largest Economy This Year. So What?A World Bank study shows China could become the world's largest economy in purchasing power parity terms in 2014. But Chinese growth means good news for the U.S. economy -- and big rewards for smart investors.
May 2, 2014 by Dan CarrollMerck's Drug Failure, Chevron's Earnings Plunge Lead the Dow's FallDespite a strong jobs report, most stocks turn into the red as the Dow ends the week on a down note
May 1, 2014 by Dan CarrollDow Falls as Strong April PMI Report Can't Outweigh Exxon's Earnings DipStocks tumble across the Dow today as Exxon misses analyst projections on its top line and sees profit fall.
Apr 30, 2014 by Dan CarrollBig Pharma's Fall Slows the Dow's MomentumThe Dow Jones ticks higher, but Merck and Pfizer lead a large corps of blue-chip laggards
Apr 29, 2014 by Dan CarrollCan Lexicon Pharmaceuticals Challenge Big Pharma?Lexicon Pharmaceuticals has taken a tumble on the market as of late, but here are three keys you need to watch on whether this stock can turn it around in the coming future.
Apr 29, 2014 by Dan CarrollWill These 3 Drugs Keep AbbVie's Future Bright After Humira?While generic drugmakers will have a whale of a challenge creating a biosimilar of AbbVie's star drug Humira, this big pharma's thinking ahead with three up-and-coming drugs developing in its pipeline.
Apr 29, 2014 by Dan CarrollBetter Biotech Buy: Vertex Pharmaceuticals Incorporated vs. BioMarin Pharmaceutical Inc.Two biotech stocks with significant interest in orphan drugs have stumbled over the past year, but can either Vertex or BioMarin turn it around for investors in the coming year?
Apr 29, 2014 by Dan CarrollMerck's Earnings Beat Leads the Dow's BounceIBM and Merck lift the Dow on a strong day around the market, while Sprint gains 10% after an earnings bounce that doesn't tell the whole story.
Apr 28, 2014 by Dan CarrollIs Alexion Pharmaceuticals Inc Poised for Years of Dominance?Between cost-cutting, earnings gains, and Soliris' huge potential, Alexion could become the darling of the biotech sector over the next half-decade.
Apr 28, 2014 by Dan CarrollPfizer's Acquisition Aims Can't Prop up the DowGoldman Sachs and the financial sector tumble today as the Dow Jones loses early momentum to stay just over breakeven.
Apr 27, 2014 by Dan CarrollWill Washington Stamp Out the E-Cigarette Boom?With the FDA proposing regulation over this up-and-coming industry, should tobacco investors be worried about their favorite stocks?
Apr 25, 2014 by Dan CarrollThe Battle for This Huge Market Just Got HotterWith Zimmer's acquisition of Biomet, this orthopedics company rises into the top tier of device makers and squares off against some formidable rivals.
